Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.

Autor:	Linde L; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark.; DANBIO Registry, Rigshospitalet, Glostrup, Denmark., Ørnbjerg LM; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark.; DANBIO Registry, Rigshospitalet, Glostrup, Denmark., Georgiadis S; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark.; DANBIO Registry, Rigshospitalet, Glostrup, Denmark., H Rasmussen S; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark., Lindström U; Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden., Askling J; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Michelsen B; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark.; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.; Research Unit, Sørlandet Hospital, Kristiansand, Norway., Di Giuseppe D; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Wallman JK; Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden., Gudbjornsson B; Centre for Rheumatology Research, Landspitali, University Hospital, Reykjavik, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Love TJ; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Department for Science and Research, Landspitali University Hospital, Reykjavik, Iceland., Nordström DC; Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland., Yli-Kerttula T; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland., Nekvindová L; Institute of Rheumatology, Prague, Czech Republic.; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Vencovský J; Institute of Rheumatology, Prague, Czech Republic.; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Iannone F; Rheumatology Unit, DETO, University of Bari, Bari, Italy., Cauli A; Rheumatology Unit, Department of Medical Sciences and Public Health, AOU and University of Cagliari, Monserrato, Italy., Loft AG; Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Glintborg B; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark.; DANBIO Registry, Rigshospitalet, Glostrup, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Laas K; Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia., Rotar Z; Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Tomšič M; Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Macfarlane GJ; Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK., Möller B; Department for Rheumatology and Immunology, Inselspital, University Hospital Bern, on behalf of the Swiss Clinical Quality Management for Rheumatic Diseases, SCQM, Zürich, Switzerland., van de Sande M; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Institute for Infection & Immunity, Amsterdam, The Netherlands.; Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, The Netherlands., Codreanu C; Center for Rheumatic Diseases, University of Medicine and Pharmacy, Romanian Registry of Rheumatic Diseases, Bucharest, Romania., Nissen MJ; Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland., Birlik M; Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey., Erten S; Department of Rheumatology, Ankara Yıldırım Beyazıt University Ankara City Hospital, Ankara, Turkey., Santos MJ; Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal.; Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal., Vieira-Sousa E; Department of Rheumatology, Hospital de Santa Maria, CHULN, Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal., Hetland ML; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Østergaard M; Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Mar 01; Vol. 63 (3), pp. 751-764.
DOI:	10.1093/rheumatology/kead284
Abstrakt:	Objectives: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results: In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98-0.99). Conclusion: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level. (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu